The first half of 2025 has been marked by a surge in strategic activity across the global healthcare, life sciences, and ...

Here, Michelle Tsai – chief operating officer at iOnctura – and Shane Olwill – chief development officer at Asgard ...

Onsite in Chicago at ASCO 2025, web editor Nicole Raleigh sat down with Dr Danny Nguyen, medical oncologist and haematologist ...

The Association of the British Pharmaceutical Industry (ABPI) has said that the new 10-year plan for the NHS has underplayed ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

A European pharma trade organisation has said that a new strategy launched by the EU to bolster the region's standing in life ...

Kymera is celebrating the signing of two partnerships, with Gilead taking an option on one molecular glue programme, as Sanofi buys into another ...

A history of NovartisNovartis is one of the world's top pharmaceutical companies, and along with neighbours Roche, the mainstay of Switzerland's centuries-long contribution to new medicines ...

Ireland is attracting major investment from the largest pharma companies in the world. Ben Hargreaves finds out how the country has become one of the most significant locations in ...

Together, these policies signal a new era of pricing accountability and regulatory oversight, with significant implications for drug development strategies, market access, and patient affordability.

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp ...